Skip to main content

Table 2 Changes in pulmonary function and other indicators per year before and after sirolimus treatment

From: Long-term efficacy and safety of sirolimus therapy in patients with lymphangioleiomyomatosis

Variables Before treatment After treatment Before vs. After
Mean change per year §P value Mean change per year §P value P value
FEV1(ml) -178 ± 36 <  0.001 − 10 ± 15 0.53 <  0.001
FVC (ml) −72 ± 68 0.29 54 ± 22 0.016 0.017
FEV1%pred −7.71 ± 1.20 <  0.001 0.29 ± 0.48 0.42 <  0.001
FVC%pred −4.11 ± 1.15 0.009 2.78 ± 0.72 < 0.001 0.008
FEV1/FVC (%) −7.34 ± 1.08 <  0.001 −1.40 ± 0.40 < 0.001 <  0.001
DLCO%pred −4.12 ± 1.10 0.002 −0.32 ± 0.37 0.40 0.017
PaO2 (mmHg) −5.7 ± 1.3 <  0.001 1.8 ± 0.5 < 0.001 0.002
P(A-a)O2 (mmHg) 4.5 ± 1.3 0.002 −1.3 ± 0.5 0.012 0.002
6MWD (m) −21 ± 6 <  0.001 15 ± 3 < 0.001 <  0.001
SGRQ total score 3.29 ± 2.02 0.11 − 2.65 ± 0.68 < 0.001 <  0.001
VEGF-D (pg/ml) − 233 ± 185 0.22 − 555 ± 96 < 0.001 <  0.001
  1. Data: mean ± SD. Data were obtained by using mixed-effects models. §P was calculated against a slope = 0. P was calculated by the slope before sirolimus therapy versus the slope after sirolimus therapy